Safety and efficacy of New-Fill® (Polylactic acid) in the treatment of HIV-associated lipoatrophy of the face (HALF)

被引：0
|
作者：
Engelhard, P [1 ]
Knies, M [1 ]
机构：
[1] Apex S Beach, Miami Beach, FL USA
来源：
XIV INTERNATIONAL AIDS CONFERENCE: CLINICAL SCIENCES AND CARE | 2002年
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Various techniques have been employed in an attempt to correct the cosmetic facial defects caused by HIV-Associated Lipoatrophy of the Face (HALF) (1). This study presents data regarding the short-term (6 month) efficacy and safety of New-Fill(R) (Polylactic Acid) in the treatment of HALF. Overall, treatment with New-Fill(R) results in significant improvement in subject self-reported lipoatrophy rating and good subject satisfaction with treatment outcome at 6 months.
引用
收藏
页码：365 / 367
页数：3
相关论文
共 50 条
  • [11] Injectable hyaluronic acid for the correction of HIV-associated facial lipoatrophy
    Denton, Andrew B.
    Tsaparas, Yotis
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2007, 136 (04) : 563 - 567
  • [12] Efficacy and impact of retreatment with poly-L-lactic acid in persons with HIV-associated facial lipoatrophy
    Mest, Douglas R.
    Humble, Gail
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB34 - AB34
  • [13] Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome
    Feldt T.
    Oette M.
    Kroidl A.
    Goebels K.
    Fritzen R.
    Kambergs J.
    Kappert G.
    Vogt C.
    Wettstein M.
    Häussinger D.
    Infection, 2006, 34 (2) : 55 - 61
  • [14] Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome
    Feldt, T.
    Oette, M.
    Kroidl, A.
    Goebels, K.
    Fritzen, R.
    Kambergs, J.
    Kappert, G.
    Vogt, C.
    Wettstein, M.
    Haeussinger, D.
    INFECTION, 2006, 34 (02) : 55 - 61
  • [15] Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome?
    Mantzoros, Christos S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (04): : 1089 - 1091
  • [16] Development of multiple lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatrophy
    Mafong, DD
    Lee, GA
    Yu, S
    Tien, P
    Mauro, T
    Grunfeld, C
    AIDS, 2004, 18 (12) : 1742 - 1744
  • [17] Polylactic acid injections (Newfill®) in the treatment of facial lipoatrophy in HIV-positive patients
    Bodokh, I.
    Simonet, P.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2006, 133 (05): : 429 - 432
  • [18] Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients
    Lafaurie, M
    Dolivo, M
    Porcher, R
    Rudant, JR
    Madelaine, I
    Molina, JM
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (04) : 393 - 398
  • [19] Treatment of HIV-related facial lipoatrophy: incidence of subcutaneous papules associated with polylactic acid treatment decreases with facial massage
    Unemori, P
    Eden, C
    Conant, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB154 - AB154
  • [20] Safety and efficacy of HIV facial lipoatrophy treatment with a volumizing hyaluronic acid filler: Final study results
    Ho, Derek
    Jagdeo, Jared
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB224 - AB224
12345